ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory

Grant

Date/time Interval

  • February 26, 2018 - February 25, 2022
  • Total Award Amount

  • 22900.00
  • Direct Costs

  • 16838.00
  • Sponsor Award Id

  • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Whelan M.D., Kimberly   Investigator